AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy

Stay informed on the latest information, including news related to AFINITOR and other updates.

European Summary of Product Characteristics

AFINITOR^® (everolimus) Summary of Product Characteristics — AFINITOR 5 mg tablets (pdf)

AFINITOR^® (everolimus) Summary of Product Characteristics — AFINITOR 10 mg tablets (pdf)

Disclaimer: This is an international website for AFINITOR^® (everolimus) tablets and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the left corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

NovartisOncology.com | About Novartis Oncology | Contact Us | Site Map
Use of website is governed by the Terms of Use and Privacy Policy
© 2010 Novartis AG